Clinical Trial

Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of MBX 2109 in patients with hypoparathyroidism who completed the 12-week treatment period in the Phase 2 study, MBX-2H1002.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2024-07-30; most recent amendment 2025-10-24.
Status change: Recruiting → Active, Not Recruiting 2025-10-24
Status change: Not Yet Recruiting → Recruiting 2024-11-04
Trial Details
NCT Number NCT06531941
Lead Sponsor MBX Biosciences
Conditions Hypoparathyroidism
Enrollment 60 participants
Start Date 2024-10-31
Primary Completion 2027-05-27 (estimated)
Study Completion 2027-05-27 (estimated)
Updated on ClinicalTrials.gov 2025-10-28